Exhibit 99.1
News From
![[ex99003.jpg]](https://capedge.com/proxy/8-K/0000950156-10-000039/ex99003.jpg)
Buena, NJ 08310
Release Date: March 30, 2010
Contact:
Philip S. Forte
IGI Laboratories, Inc.
(856) 697-4379
www.igilabs.com
IGI LABORATORIES RAISES $1.55 MILLION THROUGH PRIVATE PLACEMENT
(BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG) today announced that it has raised $1,550,000 through the private placement of Series C Convertible Preferred Stock. The investors included investment funds affiliated with Signet Healthcare Partners, G.P., the Company’s majority stockholder, and Jane E. Hager, a director and stockholder of the Company. Each share of Series C Preferred Stock is convertible into shares of common stock equal to (i) 1,000 plus any accrued and unpaid dividends, divided by (ii) $0.69 (the closing price of the Company’s common stock on the date of issuance). The Series C Preferred Stock will accrue dividends at an annual rate of 5%.
The shares of Series C Convertible Preferred Stock offered by IGI in this transaction have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company has agreed with the investors to register the shares of common stock underlying the Series C Convertible Preferred Stock.
This press release is being issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About IGI Laboratories, Inc.
IGI Laboratories, Inc. engages in the development, manufacturing, filling, and packaging of topical, semi solid and liquid products for pharmaceutical and cosmeceutical companies. The Company offers the patented Novasome® encapsulation technology which contributes value-added qualities to pharmaceutical and cosmeceutical products, providing improved dermal absorption and sustained release of the active molecule.
IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as f iled with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.’s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.